@article{fdi:010054085,
  title = {{H}igh prevalence of {HIV}-1 drug resistance among patients on first-line antiretroviral treatment in {L}ome, {T}ogo},
  author = {{D}agnra, {A}. {Y}. and {V}idal, {N}icole and {M}ensah, {A}. and {P}atassi, {A}. and {A}ho, {K}. and {S}alou, {M}. and {M}onleau, {M}arjorie and {P}rince-{D}avid, {M}. and {S}ingo, {A}. and {P}itche, {P}. and {D}elaporte, {E}ric and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {W}ith widespread use of antiretroviral ({ARV}) drugs in {A}frica, one of the major potential challenges is the risk of emergence of {ARV} drug-resistant {HIV} strains. {O}ur objective is to evaluate the virological failure and genotypic drug-resistance mutations in patients receiving first-line highly active antiretroviral therapy ({HAART}) in routine clinics that use the {W}orld {H}ealth {O}rganization public health approach to monitor antiretroviral treatment ({ART}) in {T}ogo. {M}ethods: {P}atients on {HAART} for one year (10-14 months) were enrolled between {A}pril and {O}ctober 2008 at three sites in {L}ome, the capital city of {T}ogo. {P}lasma viral load was measured with the {N}ucli{SENS} {E}asy{Q} {HIV}-1 assay ({B}iomerieux, {L}yon, {F}rance) and/or a {G}eneric viral load assay ({B}iocentric, {B}andol, {F}rance). {G}enotypic drug-resistance testing was performed with an inhouse assay on plasma samples from patients with viral loads of more than 1000 copies/ml. {CD}4 cell counts and demographic data were also obtained from medical records. {R}esults: {A} total of 188 patients receiving first-line antiretroviral treatment were enrolled, and 58 (30.8%) of them experienced virologic failure. {D}rug-resistance mutations were present in 46 patients, corresponding to 24.5% of all patients enrolled in the study. {A}ll 46 patients were resistant to non-nucleoside reverse-transcriptase inhibitors ({NNRTI}s): of these, 12 were resistant only to {NNRTI}s, 25 to {NNRTI}s and lamivudine/emtricitabine, and eight to all three drugs of their {ARV} regimes. {I}mportantly, eight patients were already predicted to be resistant to etravirine, the new {NNRTI}, and three patients harboured the {K}65{R} mutation, inducing major resistance to tenofovir. {C}onclusions: {I}n {T}ogo, efforts to provide access to {ARV} therapy for infected persons have increased since 2003, and scaling up of {ART} started in 2007. {T}he high number of resistant strains observed in {T}ogo shows clearly that the emergence of {HIV} drug resistance is of increasing concern in countries where {ART} is now widely used, and can compromise the long-term success of first-and second-line {ART}.},
  keywords = {},
  booktitle = {},
  journal = {{J}ournal of the {I}nternational {A}ids {S}ociety},
  volume = {14},
  numero = {},
  pages = {30},
  ISSN = {1758-2652},
  year = {2011},
  DOI = {10.1186/1758-2652-14-30},
  URL = {https://www.documentation.ird.fr/hor/fdi:010054085},
}